WO2016010451A1 - Поликомплексный гель для лечения заболеваний кишечно-пищеварительного тракта - Google Patents
Поликомплексный гель для лечения заболеваний кишечно-пищеварительного тракта Download PDFInfo
- Publication number
- WO2016010451A1 WO2016010451A1 PCT/RU2014/000708 RU2014000708W WO2016010451A1 WO 2016010451 A1 WO2016010451 A1 WO 2016010451A1 RU 2014000708 W RU2014000708 W RU 2014000708W WO 2016010451 A1 WO2016010451 A1 WO 2016010451A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gel
- intestinal
- thymogen
- treatment
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the invention relates to the pharmaceutical industry and is a rectal gel-like agent for the treatment of diseases of the gastrointestinal tract, including ulcerative colitis, Crohn's disease, fistulas, etc., as well as complications during the course of the above diseases.
- the invention provides an antimicrobial and antiprotozoal effect, and also has good penetrating ability.
- Non-infectious inflammatory diseases of the gastrointestinal tract which include ulcerative colitis and Crohn's disease, have been and remain one of the most serious problems of modern gastroenterology.
- ulcerative colitis and Crohn’s disease The incidence of ulcerative colitis and Crohn’s disease is increasing every year, especially among the able-bodied population, which makes them socially significant diseases.
- ulcerative colitis inflammation captures exclusively the mucous membrane of the colon, sequentially spreading from its distal to the proximal part, in severe cases covering the entire colon, including the rectum.
- the inflammatory process can affect any part, from the mouth to the anus. Most often, with this disease, a combined lesion of the lower parts of the small intestine and colon is observed, with segmented localization of the lesions, when places with an unchanged mucosa are found next to the affected area.
- various drugs are used, in particular, the drug known as sulfasalazine (Encyclopedia of drugs. Russian Drug Register PJIC, Moscow, LLC RLS-2005, 2004, 12th edition, pp. 826-827), which has antibacterial and anti-inflammatory effect.
- 5-aminosalicylic acid 5-ASA
- sulfasalazine 5-aminosalicylic acid
- sulfapyridine a competitive paraaminobenzoic acid antagonist that stops the synthesis of folates in microorganism cells and causes antibacterial activity.
- 5-ASA 5-aminosalicylic acid
- the disadvantages of the drug in the treatment of ulcerative colitis and Crohn's disease are a strong dependence on the state of intestinal normoflora, which is involved in the biotransformation of sulfasalazine and the release of the active component - 5-ASA, while the second component of the drug sulfapyridine inhibits bacteria, actually inhibits and stops the specific activity of the drug.
- allergic manifestations, dyskinetic disorders are sharply enhanced and liver function is impaired.
- the drug Salofalk is known - tablets, coated with a membrane, soluble in the intestine, containing mesalazine - 5-aminosalicylic acid. (Encyclopedia of Medicines. Russian Medicines Radar Register of Medicines, Moscow, 000 Radars-2005, 2004, 12th edition, pp. 780-781).
- the drug is an anti-inflammatory drug that inhibits the synthesis of arachidonic acid metabolites, the activity of neutrophilic lipoxygenase, inhibits the migration, degranulation and phagocytosis of neutrophils, the secretion of immunoglobulins by lymphocytes, binds and destroys free oxygen radicals. It is indicated for the treatment of ulcerative colitis and Crohn's disease.
- the objective of the invention is to provide a drug for the treatment of inflammatory diseases of the digestive tract, which does not have these drawbacks, and also has antimicrobial, local anesthetic and anti-inflammatory properties, does not cause an active skin anaphylaxis reaction and does not irritate the rectal mucosa.
- the technical result achieved by the implementation of the claimed invention is to increase the effectiveness of treatment of non-infectious inflammatory bowel diseases and reduce treatment time due to the absence of side effects and complications, which is achieved by an integrated approach to the formation of a set of components and is confirmed by the data of examinations of patients who underwent treatment with these drugs, independent experts.
- the technical result consists in providing the complex effect of the drug both on the intestinal mucosa and on the submucous layer, due to which a stable therapeutic effect is achieved and conditions are created for the prevention of relapses.
- the multicomplex gel for the treatment of diseases of the gastrointestinal tract contains, as active substances, metronidazole and thymogen and auxiliary substances in the following composition and component ratio with a total gel mass of 150 g, in g:
- Metronidazole - has an antimicrobial and antiprotozoal effect.
- the mechanism of action is the penetration of the nitro group of the drug into the respiratory chain of protozoa and anaerobes.
- respiratory processes in microorganisms are disrupted, which contributes to cell death.
- the drug disrupts DNA synthesis, which causes its degradation.
- Metronidazole is active against: protozoa (Trichomonas vaginalis, Lamblia, Entamoeba histolytica, Leishmania), aerobic gram-negative microorganisms (bacteroids Bacteroides fragilis, B. caccae, B. uniformis, B. fragilis, B.
- Timogen - has an immunomodulatory effect and is a dipeptide that affects the reactions of cellular, humoral immunity and nonspecific resistance of the body. It stimulates the regeneration processes in the event of inhibition, improves the course of cellular metabolism.
- lymphoid cells It enhances the processes of differentiation of lymphoid cells, has the ability to stimulate the colony forming activity of bone marrow cells, induces the expression of differentiation receptors on lymphocytes, normalizes the number of T-helpers, T-suppressors and their ratio in patients with various immunodeficiency states.
- Carbopol which is used as a gelling agent, because it has a dynamic yield strength and plastic viscosity.
- Disodium salt of EDTA (Trilon B) was introduced with the gel composition due to the fact that traces of metals of variable valency are possible in the components used, which provoke oxidation processes.
- the main advantage of the claimed multicomplex gel is its effectiveness against the background of the absence of side effects and complications, which is achieved by an integrated approach to the formation of a set of components and is confirmed by the data of examinations of patients who underwent treatment with these drugs, independent specialists. It is also advisable to separately note the complex effect of the claimed multicomplex gel both on the intestinal mucosa and on the submucous layer, due to which a lasting therapeutic effect is achieved, and conditions are created for the prevention of relapses. An important point is that ulcerative colitis is an autoimmune disease, and the presence of thymogen in the gel blocks the development of autoimmune local reactions. Thus, the pathological vicious circle is broken, and the conditions for normalizing the intestinal wall are created.
- metronidazole in the gel, which allows you to restore damaged structures of both the mucous membrane and submucosal layer, and also has antimicrobial and antiprotozoal action.
- the mechanism of action is the penetration of the nitro group of the drug into the respiratory chain of protozoa and anaerobes.
- metronidazole and thymogen has an extensive complex therapeutic effect, normalizes the ionic, acid-base and salt balance, stabilizing the cell membrane, inactivating cytokines and inflammatory mediators.
- the main advantage of the claimed multicomplex gel is its complex effect on all colon homeostasis systems.
- Polycomplex gel for the treatment of diseases of the gastrointestinal tract belongs to the class of substances that regulate interstitial metabolism at the level of intracellular metabolism, stabilizing the water-electrolyte, acid-base balance, stabilizing the cell membrane and reducing the manifestations of the inflammatory reaction, reducing the concentration of pro-inflammatory cytokines, prostaglandins and other mediators of inflammation in the tissues.
- the mechanism of the therapeutic effect of the drug is associated with stabilization of the cell membrane of the microvasculature, improvement of rheological properties in the capillary network of the mucous membrane of the colon and in blocking the primary autoimmune inflammatory reaction in the colon wall, which ultimately leads to a stop of pathological processes in the colon wall, normalization tissue metabolism and the reverse development of pathological processes.
- the claimed multicomplex gel is characterized by the absence of allergenic properties. Teaching that today an indispensable step in the study of a new drug is to assess its allergenicity, the claimed multicomplex gel was tested based on the Artyus-Sakharov test. For this purpose, thymogen at a dose of 10 mg / kg in 1.0 ml of isotonic sodium chloride solution on the one hand and 1 ml of horse serum under the skin of the back, on the other hand, was sterilely injected into six rabbits of both sexes weighing 2.0-2.5 kg side.
- thymogen rabbits of the control group were injected with 1 ml of isotonic sodium chloride solution. Thymogen and horse serum injections were repeated 6 times with an interval of 5-6 days. At the injection site of horse serum in rabbits of both groups, the same local reaction was observed in the form of hyperemia, hemorrhage and swelling. At the injection site of thymogen and isotonic sodium chloride solution, no reactions were detected. Prolonged intravenous administration of thymogen in three courses of 5 days each with an interval of 7 days was not accompanied by an increase in the titer of allergic agglutinating autoantibodies.
- thymogen is not allergenic. Moreover, in subsequent clinical observations, it was found that thymogen has certain desensitizing properties, which allowed its use in the treatment of atopic conditions.
- Active cutaneous anaphylaxis Active skin anaphylaxis was studied according to the “Guidelines for assessing the allergenic properties of drugs” on guinea pigs of both sexes weighing 250-300 g. Animal sensitization was carried out by rectal administration of the drug for 21 days.
- the dosage of the multicomplex gel is determined on the basis of the therapeutic dose for humans according to the active substance - metronidazole (100 mg or 1.43 mg / kg), so for guinea pigs the therapeutic dose, taking into account the species conversion factor of 4.7, is 6.7 mg / kg. 2 doses were used for sensitization: therapeutic - 6.7 mg / kg and double - 13.4 mg / kg.
- Group 1 - control administration of a placebo gel
- the guinea pigs were cut out their hair, and then 50 ⁇ l of the studied multicomplex gel was injected intradermally. To control skin reactivity, 50 ⁇ l of placebo gel was administered to the same animal in another area.
- the size of the stained spots on the inner surface of the skin at the site of permitting injection in sensitized animals did not outperform those in animals of the control group.
- the data obtained indicate that the studied multicomplex gel does not cause an active skin anaphylaxis reaction in guinea pigs.
- the multicomplex gel for the treatment of ulcerative colitis underwent an assessment of the local irritant effect, which was carried out during the study of subchronic toxicity in rabbits. Since, the studied drug is presented in the dosage form “rectal gel”, i.e. developed for rectal route of administration, local irritant action was evaluated according to the state of the rectal mucosa. For this, after euthanasia and necroscopy using a binocular lens, a visual examination of the rectal mucosa was performed to identify petechiae (small focal hemorrhages) and ulcerative lesions of the mucosa. It was shown that both in the control groups (placebo) of animals and in the groups of animals that received the studied drug, the rectal mucosa without edema, hemorrhages and ulcerations.
- a comparative histological analysis showed that cytomorphological changes under the influence of the studied drug in the studied internal organs and tissues do not develop.
- a multicomplex gel for the treatment of ulcerative colitis is used rectally daily (evening) 1 time per day.
- the course of treatment is determined by the severity of the disease.
- a multicomplex gel of the following composition can be used:
- a polycomplex gel of the following composition can be used:
- a polycomplex gel of the following composition can be used:
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112017000656-1A BR112017000656A2 (pt) | 2014-07-15 | 2014-09-23 | gel policomplexo para o tratamento de doenças do trato intestinal/digestivo |
AU2014400868A AU2014400868A1 (en) | 2014-07-15 | 2014-09-23 | Polycomplex gel for treating diseases of intestinal/digestive tract |
US15/326,289 US20170209417A1 (en) | 2014-07-15 | 2014-09-23 | Polycomplex gel for treating diseases of intestinal/digestive tract |
EA201700041A EA201700041A1 (ru) | 2014-07-15 | 2014-09-23 | Поликомплексный гель для лечения заболеваний кишечно-пищеварительного тракта |
JP2016576029A JP2017526637A (ja) | 2014-07-15 | 2014-09-23 | 腸/消化管疾患治療用のポリ複合ゲル |
CN201480080577.6A CN107072943A (zh) | 2014-07-15 | 2014-09-23 | 用于治疗肠道/消化道疾病的多聚复合物凝胶 |
EP14897556.8A EP3170491A1 (en) | 2014-07-15 | 2014-09-23 | Polycomplex gel for treating diseases of intestinal/digestive tract |
CA2954980A CA2954980A1 (en) | 2014-07-15 | 2014-09-23 | Polycomplex gel for treating diseases of intestinal/digestive tract |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014128856/15A RU2605615C2 (ru) | 2014-07-15 | 2014-07-15 | Ректальный поликомплексный гель для лечения язвенного колита, болезни крона, свищей и осложнений, вызванных этими заболеваниями |
RU2014128856 | 2014-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016010451A1 true WO2016010451A1 (ru) | 2016-01-21 |
Family
ID=55078823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2014/000708 WO2016010451A1 (ru) | 2014-07-15 | 2014-09-23 | Поликомплексный гель для лечения заболеваний кишечно-пищеварительного тракта |
Country Status (10)
Country | Link |
---|---|
US (1) | US20170209417A1 (ru) |
EP (1) | EP3170491A1 (ru) |
JP (1) | JP2017526637A (ru) |
CN (1) | CN107072943A (ru) |
AU (1) | AU2014400868A1 (ru) |
BR (1) | BR112017000656A2 (ru) |
CA (1) | CA2954980A1 (ru) |
EA (1) | EA201700041A1 (ru) |
RU (1) | RU2605615C2 (ru) |
WO (1) | WO2016010451A1 (ru) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843482A (en) * | 1990-07-20 | 1998-12-01 | Tillotts Pharma Ag | Products and processes for the treatment of the alimentary canal |
RU2445965C2 (ru) * | 2010-07-05 | 2012-03-27 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Пероральная фармацевтическая композиция для лечения воспалительных заболеваний желудочно-кишечного тракта |
WO2013012662A2 (en) * | 2011-07-15 | 2013-01-24 | S.L.A. Pharma Ag | Pharmaceutical compositions for rectal administration |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023271A (en) * | 1985-08-13 | 1991-06-11 | California Biotechnology Inc. | Pharmaceutical microemulsions |
US6689788B1 (en) * | 2000-08-25 | 2004-02-10 | University Of Florida | Method and composition for treatment of inflammatory bowel disease |
US20060240123A1 (en) * | 2002-08-26 | 2006-10-26 | S.L.A. Pharma Ag | Pharmaceutical composition |
AU2005311769A1 (en) * | 2004-12-02 | 2006-06-08 | Isis Pharmaceuticals, Inc. | Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease |
MX2010009197A (es) * | 2008-02-26 | 2010-11-22 | Salix Pharmaceuticals Ltd | Metodos para tratar padecimientos del intestino. |
-
2014
- 2014-07-15 RU RU2014128856/15A patent/RU2605615C2/ru not_active IP Right Cessation
- 2014-09-23 CA CA2954980A patent/CA2954980A1/en not_active Abandoned
- 2014-09-23 US US15/326,289 patent/US20170209417A1/en not_active Abandoned
- 2014-09-23 EP EP14897556.8A patent/EP3170491A1/en not_active Withdrawn
- 2014-09-23 WO PCT/RU2014/000708 patent/WO2016010451A1/ru active Application Filing
- 2014-09-23 AU AU2014400868A patent/AU2014400868A1/en not_active Abandoned
- 2014-09-23 CN CN201480080577.6A patent/CN107072943A/zh active Pending
- 2014-09-23 EA EA201700041A patent/EA201700041A1/ru unknown
- 2014-09-23 JP JP2016576029A patent/JP2017526637A/ja active Pending
- 2014-09-23 BR BR112017000656-1A patent/BR112017000656A2/pt not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843482A (en) * | 1990-07-20 | 1998-12-01 | Tillotts Pharma Ag | Products and processes for the treatment of the alimentary canal |
RU2445965C2 (ru) * | 2010-07-05 | 2012-03-27 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Пероральная фармацевтическая композиция для лечения воспалительных заболеваний желудочно-кишечного тракта |
WO2013012662A2 (en) * | 2011-07-15 | 2013-01-24 | S.L.A. Pharma Ag | Pharmaceutical compositions for rectal administration |
Non-Patent Citations (1)
Title |
---|
"Instruktsiya po meditsinskomu primeneniju preparata Metrogil", 17 February 2007 (2007-02-17), XP008184224, Retrieved from the Internet <URL:http://grls.rosminzdrav.ralAnstrImgMZ.aspx?regNr=%D0%9F% 20N011666/02&page=1> * |
Also Published As
Publication number | Publication date |
---|---|
US20170209417A1 (en) | 2017-07-27 |
CN107072943A (zh) | 2017-08-18 |
BR112017000656A2 (pt) | 2018-01-09 |
JP2017526637A (ja) | 2017-09-14 |
AU2014400868A1 (en) | 2017-03-02 |
EP3170491A1 (en) | 2017-05-24 |
CA2954980A1 (en) | 2016-01-21 |
RU2605615C2 (ru) | 2016-12-27 |
RU2014128856A (ru) | 2016-02-10 |
EA201700041A1 (ru) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moloney et al. | Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities | |
US20170189428A1 (en) | Dialkyl-phosphinoyl-alkane (Dapa) compounds and compositions for treatment of lower gastrointestinal tract disorders | |
WO1984002470A1 (en) | Medicinal preparation for the therapeutic treatment of peptic ulcer | |
Zhao et al. | Anti-arthritic effects of microneedling with bee venom gel | |
Hymel et al. | Stress-induced increases in depression-like and ***e place-conditioned behaviors are reversed by disruption of memories during reconsolidation | |
WO2016010451A1 (ru) | Поликомплексный гель для лечения заболеваний кишечно-пищеварительного тракта | |
US20130289023A1 (en) | Method for treating brain tumor | |
Winter et al. | Effect of sedation protocol on glomerular filtration rate in cats as determined by use of quantitative renal scintigraphy | |
Basu et al. | Euphorbia bicolor (Euphorbiaceae) latex extract reduces inflammatory cytokines and oxidative stress in a rat model of orofacial pain | |
Xu et al. | Diosgenin exerts an antihypertensive effect in spontaneously hypertensive rats via gut–brain communication | |
Mahardian et al. | Bisacodyl overcomes morphine-induced constipation by decreasing colonic Aquaporin-3 and Aquaporin-4 expression | |
CN114028416A (zh) | 一种用于治疗化疗诱发的外周神经病变的组合物及其应用 | |
JP2011520881A (ja) | 認知機能を改善するための方法および組成物 | |
Kovac et al. | Current strategies for prevention and treatment of equine postoperative ileus: a multimodal approach | |
Gójska-Zygner et al. | Canine iatrogenic persistent hypoadrenocorticism after short-term treatment of hyperadrenocorticism with trilostane-a case report | |
WO2015199248A1 (ja) | 発汗抑制剤 | |
Rahmadi et al. | Bisacodyl overcomes morphine-induced constipation by decreasing colonic Aquaporin-3 and Aquaporin-4 expression. Research Results in Pharmacology 8 (4): 65–75 | |
Skelly | Hypoparathyroidism | |
Ahmad et al. | Comparison of the effects of butorphanol–midazolam–medetomidine and butorphanol–azaperone–medetomidine in wild common palm civets (Paradoxurus musangus) | |
McCall et al. | Determining the response of central amygdala dynorphin neurons to stress and pain | |
RU2782488C1 (ru) | Способ внутрибрюшинного применения медицинского озона для лечения язвенного колита | |
Burda et al. | The end effector of ischemic tolerance present in blood plasma from double conditioned donors ameliorates trimethyltin provoked damage in brain | |
WO2017080989A1 (en) | (r)-fluriprofen for the prevention and/or treatment of diabetes | |
Rahmadi et al. | Bisacodyl overcomes morphine-induced Bisacodyl overcomes morphine-induced constipation by decreasing colonic Aquaporin-3 and Aquaporin-4 expression | |
RU2645067C1 (ru) | Способ лечения больных геморрагической лихорадкой с почечным синдромом при развитии нарушений функции печени |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14897556 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016576029 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2954980 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15326289 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017000656 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201700041 Country of ref document: EA |
|
REEP | Request for entry into the european phase |
Ref document number: 2014897556 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014897556 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014400868 Country of ref document: AU Date of ref document: 20140923 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112017000656 Country of ref document: BR Free format text: REGULARIZAR O DOCUMENTO DE PROCURACAO, UMA VEZ QUE, BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA, OU SEGUNDO MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR DECLARACAO DE VERACIDADE ASSINADA POR PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO OU NO SEU SUBSTABELECIMENTO. Ref country code: BR Ref legal event code: B01E Ref document number: 112017000656 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01Y Ref document number: 112017000656 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112017000656 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170112 |